On this page
In the first head-to-head trial, tirzepatide produced more weight loss than semaglutide — about 20% of body weight versus 14% over 72 weeks. Tirzepatide wins on the average. Both are highly effective, and the better drug for one person comes down to tolerance, cost, access, and how their body responds.
For years the two leading weight-loss drugs had never been tested directly against each other, so any "which is better" answer leaned on cross-trial guesswork. That changed in 2025. Now there's a real head-to-head, and it gives a clearer picture of how semaglutide and tirzepatide stack up.
Here's the short version, then the detail behind it: tirzepatide led on average weight loss, both drugs work far better than anything that came before, and "better on average" doesn't settle which one is right for you.
Which one works better
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, was the first to randomly assign adults with obesity (and without type 2 diabetes) to either tirzepatide or semaglutide and follow them for 72 weeks. Among the 751 participants, average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide. People on tirzepatide were also more likely to hit the bigger milestones, like losing at least 15% or 20% of their starting weight.
That's a meaningful gap, and it's the strongest evidence we have. But an average is built from a wide spread of individual results. Plenty of people lose more on semaglutide than the typical tirzepatide patient does, and a few lose very little on either.
Better on average is not better for everyone. I've had patients do beautifully on semaglutide after stalling on tirzepatide, and the reverse. The trial tells you where to start the conversation, not where it ends.
— John Venzor, DO
How they actually differ
The headline numbers come from each drug's own pivotal trials, both in the New England Journal of Medicine: semaglutide produced roughly 15% average loss in the STEP 1 trial (2021), and tirzepatide's higher doses pushed past 20% in SURMOUNT-1 (2022). The reason tends to come down to how each one works. Here's a side-by-side on the points that matter most:
- Mechanism. Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist, hitting both GLP-1 and a second gut hormone receptor called GIP. That extra target is the leading theory for why it tends to produce more weight loss.
- Average weight loss. Around 14% for semaglutide and 20% for tirzepatide in the head-to-head, with a lot of person-to-person variation underneath those figures.
- Form and frequency. Both are once-weekly injections you give yourself with a small needle. Semaglutide also comes as a daily oral tablet (Rybelsus); tirzepatide is injection-only for now.
- Brand names. Semaglutide is sold as Wegovy and Ozempic (and oral Rybelsus). Tirzepatide is sold as Zepbound and Mounjaro. Read more on semaglutide and tirzepatide on their own.
- Side effects. Broadly similar. Both are mostly digestive, and most complaints show up while the dose is climbing.
- Cost and access. This often decides it in practice. Brand-name pricing, insurance coverage, and compounded availability all shift month to month. Our compounded vs. brand guide walks through where things stand.
Side effects compared
On safety and tolerability, the two are close. In SURMOUNT-5 (2025), the most common side effects in both groups were gastrointestinal. Nausea, diarrhea, constipation, and the occasional bout of vomiting topped the list, and most were mild to moderate and clustered during the weeks when the dose steps up. Going slow on the titration is the single best lever for keeping those manageable, which is why both drugs start low and build over months.
Because the profiles overlap so much, side effects rarely make the choice for you on their own. Our guide to GLP-1 side effects covers what's normal, what isn't, and how to ride out the early weeks.
Neither drug is right for everyone. Both carry a warning against use if you or a close family member has had medullary thyroid cancer or the syndrome MEN 2. Tell a clinician if you've had pancreatitis, gallbladder disease, or serious GI problems. Don't use either if you're pregnant or trying to become pregnant. Seek care promptly for severe, lasting abdominal pain, which can signal pancreatitis.
How to choose
If raw weight loss were the only factor, tirzepatide would be the default. It rarely is. As NIDDK notes in its 2025 guidance on obesity medications, the right choice depends on your health history, your other conditions, and what's actually available and affordable to you. A few things that genuinely tip the decision:
- What you've tried before. If you've stalled on one, switching to the other is a reasonable next step rather than giving up on the class.
- Needles versus pills. If a weekly injection is a dealbreaker, oral semaglutide is an option tirzepatide can't match yet.
- Cost and coverage. The cheaper drug you'll actually stay on beats the stronger drug you quit after two months.
- Your starting point and goals. Someone aiming for a large reduction may lean tirzepatide; someone who responds well and tolerates semaglutide has little reason to switch.
Both belong to the most effective category of weight-loss medication ever brought to market, and the gap between them is smaller than the gap between either one and the older options. So the strongest drug in a trial won't automatically be the strongest drug for you. Pick the one a clinician thinks fits your body, your budget, and your life, and that you can stay on long enough to see the result.